US healthcare giant Johnson & Johnson (NYSE: JNJ) subsidiary has released positive top-line results from the three-arm Phase III MARIPOSA-2 study evaluating Rybrevant (amivantamab-vmjw) in lung cancer patients.
Rybrevant, is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), given with and without lazertinib, an oral, third-generation EGFR tyrosine kinase inhibitor (TKI), combined with chemotherapy (carboplatin and pemetrexed) versus chemotherapy alone.
MARIPOSA-2 enrolled patients with locally advanced or metastatic EGFR exon 19 deletions (ex19del) or L858R substitution non-small cell lung cancer (NSCLC) after disease progression on or after osimertinib. The study met its dual primary endpoint, demonstrating a statistically-significant and clinically meaningful improvement in PFS versus chemotherapy alone in both experimental treatment arms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze